Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2C | Q14957 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ERO1A | Q96HE7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894074 | 0.87 | MAPT (0.57) | GRIN2CMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7894867 | 0.85 | MAPT (0.71) | GRIN2CMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7904120 | 0.83 | NPC1 (0.68) | GRIN2CMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7902807 | 0.83 | NPSR1 (0.61) | GRIN2CMAPTALDH1A1NPSR1KDM4E | |
| SCHEMBL7906323 | 0.83 | GRIN2C (1.00) | GRIN2CMAPTALDH1A1NPC1RAB9A | |
| SCHEMBL7894076 | 0.82 | ALDH1A1 (0.58) | MAPTALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL5788877 | 0.77 | MAPT (0.60) | MAPTALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL7894658 | 0.75 | GRIN2C (1.00) | GRIN2CMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL21411372 | 0.74 | ALDH1A1 (0.49) | MAPTALDH1A1NPC1RAB9ANPSR1 | |
| SCHEMBL14231868 | 0.74 | NPSR1 (0.46) | GRIN2CMAPTALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | TRAYNELIS STEPHEN F (US) | 2014-09-18 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822462-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | EMORY UNIVERSITY (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | EMORY UNIVERSITY (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010088414-A2 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | EMORY UNIVERSITY (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273214-B2 | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions | GRIN1, GRIN2A, GRIN2B | GRIN2C 5/4885MAPT 768/4885ALDH1A1 2048/4885 |
| US-20120028977-A1 | Subunit Selective NMDA Receptor Potentiators For The Treatment Of Neurological Conditions | GRIN1, GRIN2A, GRIN2B | GRIN2C 5/4885MAPT 768/4885ALDH1A1 2048/4885 |
| US-20140275529-A1 | SUBUNIT SELECTIVE NMDA RECEPTOR POTENTIATORS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | GRIN1, GRIN2A, GRIN2B | GRIN2C 5/4885MAPT 768/4885ALDH1A1 2048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.